Clinical trial · Observational
Sorafenib to Treat FLT3-ITD AML
Sorafenib to Treat AML Patients With FLT3-ITD Mutation: a Non-interventional Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
It is a prospective, non-interventional, open-label study, in order to observe the safety and response in FLT3-ITD mutation positive AML patients who receiving sorafenib as induction, consolidation, salvage, maintenance or alleviative treatment. The duration of the study from June 2014 through May 2019, with the recruitment duration from June 2014 to May 2017. The inclusion criteria is: 1. Definitely diagnosed as AML 2. FLT3-ITD mutation has been confirmed 3. Accepting the prescription of sorafenib
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
| FLT3-ITD Mutation | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (5)
- label
- Induction Group
- label
- Consolidation Group
- label
- Salvage Group
- label
- Maintenance Group
- label
- Alleviatitive Group
Primary outcomes (2)
- measure
- Overall Response Rate
- timeFrame
- up to 2 years
- measure
- Progress-Free Survival
- timeFrame
- up to 2 years
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Definitely diagnosed as AML * FLT3-ITD mutation has been confirmed * Accepting the prescription of sorafenib Exclusion Criteria: * Can not take drugs orally * Can not follow the doctors' advices * Other reasons that investigators considered as contra-indications for this study
References
Publications (0)
Data not yet available